Effects of FK-506 and cyclosporine on human T and B lymphoproliferative responses

Wasik, M; Stepień-Sopniewska, B; Lagodzinski, Z; Górski, Andrzej

doi:10.1016/0162-3109(90)90007-2

Cited by 21 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PBM IL-2 production was more markedly decreased following treatment with FK506 in the patients with elevated PBM IL-2 production than in those with normal PBM IL-2 production (1 month, P Ͻ 0.05) ( Table 1). Given that FK506 inhibits IL-2 production, appears to act selectively on T cells, 13,16 and inhibits T-cell-dependent antibody production, 17 the marked decrease in IL-2 production may ameliorate functional abnormalities of T cells in the pathogenesis of MG. However, the mean AChR Ab ratio did not change, and was not different between the two groups ( Table 1).…”

Section: Resultsmentioning

confidence: 98%

Effects of FK506 on myasthenia gravis patients with high interleukin‐2 productivity in peripheral blood mononuclear cells

et al. 2002

View full text Add to dashboard Cite

We compared the early effects of FK506 on clinical severity, interleukin-2 (IL-2) production by phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMs), and serum levels of acetylcholine receptor antibodies between myasthenia gravis (MG) patients with elevated (>1250 pg/ml, n = 9) or normal (<1250 pg/mL, n = 10) levels of PBM IL-2 production. Reduction in clinical severity and PBM IL-2 production were significantly greater in the patients with elevated IL-2 production than those with normal PBM IL-2 production in the first month of treatment.

show abstract

Section: Resultsmentioning

confidence: 98%

Effects of FK506 on myasthenia gravis patients with high interleukin‐2 productivity in peripheral blood mononuclear cells

et al. 2002

View full text Add to dashboard Cite

show abstract

“…CsA and FK506 have been shown to be potent inhibitors of cell-mediated immune responses and humoral responses [31,32]. The inhibition of splenomegaly and IgE in the chronic GVHR at the higher doses was expected based on the known mechanism of activity of these compounds.…”

Section: Discussionmentioning

confidence: 99%

“…The precise mechanism is unknown, but as a consequence of rapamycin activity a cellular p70 S6 protein kinase has been shown to be inhibited [27]. [31,32]. The inhibition of splenomegaly and IgE in the chronic GVHR at the higher doses was expected based on the known mechanism of activity of these compounds.…”

Section: Micementioning

confidence: 99%

The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response—anin vivomodel of Th2-like activity

Bundick¹,

Craggs²,

Holness³

1995

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYWe have evaluated the effects of three potent immunosuppressive agents: cyclosporin A, FK506, and rapamycin, on a murine chronic graft-versus-host response (chronic GVHR). The chronic GVHR has previously been described to be a Th2-like response, and is characterized by a marked splenomegaly and hyper-IgE production in the early stages of the response. The effects of the immunosuppressive agents on both splenomegaly and hyper-IgE were measured 3 weeks after the induction of the chronic GVHR. Rapamycin was found to inhibit both splenomegaly and the hyper-IgE response in a dose-dependent manner. Unexpectedly cyclosporin A and FK506 were found to potentiate markedly both the splenomegaly and hyper-IgE response at low doses before exhibiting an inhibitory effect at higher doses. We propose the differences of activity seen with rapamycin compared with cyclosporin A and FK506 may be explained by their different mechanisms of action, and also by the selectivity of low dose cyclosporin A and FK506 for Th 1-like lymphocytes. The implications of these observations are discussed in relation to the use of these immunosuppressives for the treatment of Th2-like diseases.

show abstract

“…Although structurally different, both compounds, like CsA, target the phosphatase calcineurin and subsequently inhibit the activation‐driven nuclear import of the cytosolic subunit of the transcripiton factor NFAT. Consequently, T cell proliferation and cytokine production is inhibited by both drugs in the low, or even subnanomolar range in vitro , which is up to 100‐fold more potent than CsA [94,95]. In addition, tacrolimus and pimecrolimus inhibit the release and production of preformed and soluble mediators in mast cells [96,97].…”

Section: How To Control the Effector Phase Of Skin‐infiltrating T Cells?mentioning

confidence: 99%

New treatments for atopic dermatitis

Jung¹

2002

Clin Experimental Allergy

View full text Add to dashboard Cite

Effects of FK-506 and cyclosporine on human T and B lymphoproliferative responses

Cited by 21 publications

References 5 publications

Effects of FK506 on myasthenia gravis patients with high interleukin‐2 productivity in peripheral blood mononuclear cells

Effects of FK506 on myasthenia gravis patients with high interleukin‐2 productivity in peripheral blood mononuclear cells

The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response—anin vivomodel of Th2-like activity

New treatments for atopic dermatitis

Contact Info

Product

Resources

About